Aethlon Medical Inc (AEMD)

[Truthteller]

News Blurb from Seeking Alpha:

Athlon's Hemopurifier safe in small study in HCV-infected ESRD patients; shares ahead 24%
Mar. 13, 2017 11:15 AM ET|About: Aethlon Medical, Inc. (AEMD)|By: Douglas W. House, SA News Editor

Thinly traded nano cap Aethlon Medical (AEMD +24.3%) is up on a 65% spike in volume, albeit on only 39K shares, in response to its announcement of positive results from a single-site feasibility study to evaluate the safety of its Hemopurifier in health-comprised individuals.

The study, conducted in eight patients with end-stage renal disease (ESRD) with hepatitis C virus (HCV) infection, showed the Hemopurifier was safe and well-tolerated. The final report to the FDA will include observations of viral load reduction during treatment and a quantitative post-treatment assessment of total viruses captured with the device.

The Hemopurifier targets the broad-spectrum elimination of viruses, bacterial toxins and immunosuppressive proteins from the blood.